Jen Saunders

Jen Saunders is a seasoned communications professional with extensive experience in investor relations and corporate communications, currently serving as Senior Director at Iovance Biotherapeutics, Inc. since October 2021, where Jen led the public relations efforts for the FDA approval of Amtagvi, the first one-time cell therapy for solid tumors. Prior roles include Director of Investor Relations and Public Relations at Ruder Finn, Vice President at Syneos Health Communications and Centron, and leadership positions at Medical Dynamics and Padilla Speer Beardsley, focusing on strategic communications in healthcare and biotech. Jen holds a BA in History from the University of California, Berkeley, and began a career in marketing at Atalanta Sosnoff Capital.